
Topic
Prior Authorization
Documentation, step edits, renewal cycles, appeals, and how payer criteria shape real-world drug use.

Specialty· July 11, 2026 · 16 min read
By Ran Chen#Gene Therapy#Hematology#Payer Coverage

Specialty· July 9, 2026 · 17 min read
IgA Nephropathy Access: Trutakna, Filspari, Tarpeyo, Fabhalta, and Voyxact

Specialty· July 7, 2026 · 21 min read
Voranigo (vorasidenib) Glioma Access: Pricing, Biomarker Testing, and Payer PA
By Ran Chen#Oncology#Orphan Drug#Prior Authorization

Pricing & Access· July 1, 2026 · 17 min read
CDK4/6 Inhibitor Access Landscape: Payer Dynamics After Ibrance's Expansion
By Ran Chen#Oncology#Breast Cancer#Payer Coverage

Pricing & Access· June 28, 2026 · 21 min read
Casgevy Access Guide: CMS CGT Model, State Medicaid Criteria, and the ATC Network
By Ran Chen#Medicaid#Prior Authorization#Gene Therapy

Manufacturing· June 15, 2026 · 11 min read
ADHD stimulant shortage: 222 records, 75 not fully available, 3-year median age

Evidence· June 15, 2026 · 11 min read
DOACs in FAERS: 330,426 adverse-event reports by the numbers
By Ran Chen#DOAC#Real-World Evidence#Label Warnings

Policy· June 14, 2026 · 12 min read
How to read an FDA drug label on DailyMed: indication scope, boxed warnings, and PA

Pricing & Access· June 10, 2026 · 10 min read
Bispecific antibody access landscape for myeloma and lymphoma

Pricing & Access· June 10, 2026 · 9 min read
CAR-T cell therapy access landscape: seven products in 2026
By Ran Chen#CAR-T#Oncology#Prior Authorization